{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T01:13:27Z","timestamp":1793841207736,"version":"4.6.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T00:00:00Z","timestamp":1747526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T00:00:00Z","timestamp":1747526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Anhui Provincial Health Research Program","award":["AHWJ2023A20430"],"award-info":[{"award-number":["AHWJ2023A20430"]}]},{"name":"Key Research and Development Plan of Jiangsu Province","award":["BE2019666"],"award-info":[{"award-number":["BE2019666"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00415-025-13118-9","type":"journal-article","created":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T16:11:18Z","timestamp":1747584678000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Relapses during treatment with monoclonal antibodies targeting B-cells in NMOSD"],"prefix":"10.1007","volume":"272","author":[{"given":"Shugang","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyue","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanjuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingwu","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5038-0599","authenticated-orcid":false,"given":"Yanghua","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,18]]},"reference":[{"issue":"2","key":"13118_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85(2):177\u2013189. https:\/\/doi.org\/10.1212\/WNL.0000000000001729","journal-title":"Neurology"},{"issue":"1","key":"13118_CR2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","volume":"271","author":"T K\u00fcmpfel","year":"2024","unstructured":"K\u00fcmpfel T, Giglhuber K, Aktas O et al (2024) Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD)\u2014revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. J Neurol 271(1):141\u2013176. https:\/\/doi.org\/10.1007\/s00415-023-11910-z","journal-title":"J Neurol"},{"issue":"11","key":"13118_CR3","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","volume":"73","author":"V Damato","year":"2016","unstructured":"Damato V, Evoli A, Iorio R (2016) Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. JAMA Neurol 73(11):1342\u20131348. https:\/\/doi.org\/10.1001\/jamaneurol.2016.1637","journal-title":"JAMA Neurol"},{"issue":"2","key":"13118_CR4","doi-asserted-by":"publisher","first-page":"102727","DOI":"10.1016\/j.autrev.2020.102727","volume":"20","author":"O Mirmosayyeb","year":"2021","unstructured":"Mirmosayyeb O, Shaygannejad V, Barzegar M et al (2021) Efficacy and safety of rituximab in treating patients with Neuromyelitis optica spectrum disorder (NMOSD): a systematic review and meta-analysis. Autoimmun Rev 20(2):102727. https:\/\/doi.org\/10.1016\/j.autrev.2020.102727","journal-title":"Autoimmun Rev"},{"key":"13118_CR5","doi-asserted-by":"publisher","first-page":"104321","DOI":"10.1016\/j.ebiom.2022.104321","volume":"86","author":"JL Bennett","year":"2022","unstructured":"Bennett JL, Aktas O, Rees WA et al (2022) Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: an exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2\/3 trial. EBioMedicine 86:104321. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104321","journal-title":"EBioMedicine"},{"issue":"6","key":"13118_CR6","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/S1474-4422(24)00077-2","volume":"23","author":"BAC Cree","year":"2024","unstructured":"Cree BAC, Kim HJ, Weinshenker BG, et al (2024) Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-Momentum trial. Lancet Neurol 23(6):588\u2013602. https:\/\/doi.org\/10.1016\/S1474-4422(24)00077-2","journal-title":"Lancet Neurol"},{"issue":"9","key":"13118_CR7","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","volume":"70","author":"SH Kim","year":"2013","unstructured":"Kim SH, Huh SY, Lee SJ et al (2013) A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol 70(9):1110\u20131117. https:\/\/doi.org\/10.1001\/jamaneurol.2013.3071","journal-title":"JAMA Neurol"},{"issue":"4","key":"13118_CR8","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00415-018-8771-5","volume":"265","author":"P Cabre","year":"2018","unstructured":"Cabre P, Mejdoubi M, Jeannin S et al (2018) Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study. J Neurol 265(4):917\u2013925. https:\/\/doi.org\/10.1007\/s00415-018-8771-5","journal-title":"J Neurol"},{"key":"13118_CR9","doi-asserted-by":"publisher","first-page":"103143","DOI":"10.1016\/j.msard.2021.103143","volume":"54","author":"B Shi","year":"2021","unstructured":"Shi B, Zhao M, Qiao L et al (2021) Relapses shortly after rituximab treatment in neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 54:103143. https:\/\/doi.org\/10.1016\/j.msard.2021.103143","journal-title":"Mult Scler Relat Disord"},{"issue":"9","key":"13118_CR10","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","volume":"72","author":"SH Kim","year":"2015","unstructured":"Kim SH, Jeong IH, Hyun JW et al (2015) Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: Influence of FCGR3A polymorphisms on the therapeutic response to rituximab. JAMA Neurol 72(9):989\u2013995. https:\/\/doi.org\/10.1001\/jamaneurol.2015.1276","journal-title":"JAMA Neurol"},{"key":"13118_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jneuroim.2017.12.021","volume":"316","author":"T Li","year":"2018","unstructured":"Li T, Zhang LJ, Zhang QX et al (2018) Anti-Rituximab antibody in patients with NMOSDs treated with low dose Rituximab. J Neuroimmunol 316:107\u2013111. https:\/\/doi.org\/10.1016\/j.jneuroim.2017.12.021","journal-title":"J Neuroimmunol"},{"key":"13118_CR12","doi-asserted-by":"publisher","first-page":"104524","DOI":"10.1016\/j.msard.2023.104524","volume":"70","author":"S Cao","year":"2023","unstructured":"Cao S, Wang X, Ji X et al (2023) B-cell proliferation characteristics and monitoring significance under the modified reduced-dose rituximab regimen for NMOSD: a real-world case series study. Mult Scler Relat Disord 70:104524. https:\/\/doi.org\/10.1016\/j.msard.2023.104524","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"13118_CR13","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/WCO.0000000000000694","volume":"32","author":"K Fujihara","year":"2019","unstructured":"Fujihara K (2019) Neuromyelitis optica spectrum disorders: still evolving and broadening. Curr Opin Neurol 32(3):385\u2013394. https:\/\/doi.org\/10.1097\/WCO.0000000000000694","journal-title":"Curr Opin Neurol"},{"issue":"3","key":"13118_CR14","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1212\/NXI.0000000000000104","volume":"2","author":"JL Bennett","year":"2015","unstructured":"Bennett JL, O\u2019Connor KC, Bar-Or A et al (2015) B lymphocytes in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm 2(3):e104. https:\/\/doi.org\/10.1212\/NXI.0000000000000104","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13118_CR15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/nyas.12118","volume":"1283","author":"M Mitsdoerffer","year":"2013","unstructured":"Mitsdoerffer M, Kuchroo V, Korn T (2013) Immunology of neuromyelitis optica: a T cell-B cell collaboration. Ann N Y Acad Sci 1283:57\u201366. https:\/\/doi.org\/10.1111\/nyas.12118","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"13118_CR16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00415-018-9092-4","volume":"266","author":"G Ellrichmann","year":"2019","unstructured":"Ellrichmann G, Bolz J, Peschke M et al (2019) Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica\/neuromyelitis optica spectrum disorders. J Neurol 266(1):57\u201367. https:\/\/doi.org\/10.1007\/s00415-018-9092-4","journal-title":"J Neurol"},{"issue":"4","key":"13118_CR17","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1136\/jnnp-2018-318465","volume":"90","author":"SH Kim","year":"2019","unstructured":"Kim SH, Kim Y, Kim G et al (2019) Less frequent rituximab retreatment maintains remission of neuromyelitis optica spectrum disorder, following long-term rituximab treatment. J Neurol Neurosurg Psychiatry 90(4):486\u2013487. https:\/\/doi.org\/10.1136\/jnnp-2018-318465","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"13118_CR18","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s00415-016-8188-y","volume":"263","author":"P Annovazzi","year":"2016","unstructured":"Annovazzi P, Capobianco M, Moiola L et al (2016) Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study. J Neurol 263(9):1727\u20131735. https:\/\/doi.org\/10.1007\/s00415-016-8188-y","journal-title":"J Neurol"},{"issue":"7","key":"13118_CR19","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1177\/1352458515602337","volume":"22","author":"N Collongues","year":"2016","unstructured":"Collongues N, Brassat D, Maillart E et al (2016) Efficacy of rituximab in refractory neuromyelitis optica. Mult Scler 22(7):955\u2013959. https:\/\/doi.org\/10.1177\/1352458515602337","journal-title":"Mult Scler"},{"issue":"1","key":"13118_CR20","doi-asserted-by":"publisher","first-page":"e640","DOI":"10.1212\/NXI.0000000000000640","volume":"7","author":"T Akaishi","year":"2019","unstructured":"Akaishi T, Nakashima I, Takahashi T et al (2019) Neuromyelitis optica spectrum disorders with unevenly clustered attack occurrence. Neurol Neuroimmunol Neuroinflamm 7(1):e640. https:\/\/doi.org\/10.1212\/NXI.0000000000000640","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13118_CR21","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.msard.2018.12.011","volume":"28","author":"MA Mealy","year":"2019","unstructured":"Mealy MA, Mossburg SE, Kim SH et al (2019) Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis\/preventive treatment, MRI lesion length and presence of symptomatic brain lesions. Mult Scler Relat Disord 28:64\u201368. https:\/\/doi.org\/10.1016\/j.msard.2018.12.011","journal-title":"Mult Scler Relat Disord"},{"key":"13118_CR22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1742-2094-9-14","volume":"9","author":"S Jarius","year":"2012","unstructured":"Jarius S, Ruprecht K, Wildemann B et al (2012) Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 9:14. https:\/\/doi.org\/10.1186\/1742-2094-9-14","journal-title":"J Neuroinflammation"},{"issue":"2","key":"13118_CR23","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1007\/s13311-020-00973-9","volume":"18","author":"Y Xu","year":"2021","unstructured":"Xu Y, Ren Y, Li X et al (2021) Persistently gadolinium-enhancing lesion is a predictor of poor prognosis in NMOSD attack: a clinical trial. Neurotherapeutics 18(2):868\u2013877. https:\/\/doi.org\/10.1007\/s13311-020-00973-9","journal-title":"Neurotherapeutics"},{"issue":"4","key":"13118_CR24","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1002\/acn3.52007","volume":"11","author":"S Cao","year":"2024","unstructured":"Cao S, Zhu Y, Wu X et al (2024) Asymptomatic spinal lesions in patients with AQP4-IgG-positive NMOSD: a real-world cohort study. Ann Clin Transl Neurol 11(4):905\u2013915. https:\/\/doi.org\/10.1002\/acn3.52007","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"13118_CR25","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1177\/1352458515594042","volume":"22","author":"M Radaelli","year":"2016","unstructured":"Radaelli M, Moiola L, Sangalli F et al (2016) Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients. Mult Scler 22(4):511\u2013519. https:\/\/doi.org\/10.1177\/1352458515594042","journal-title":"Mult Scler"},{"issue":"3","key":"13118_CR26","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/nrrheum.2011","volume":"7","author":"F Hiepe","year":"2011","unstructured":"Hiepe F, D\u00f6rner T, Hauser AE et al (2011) Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol 7(3):170\u2013178. https:\/\/doi.org\/10.1038\/nrrheum.2011","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"13118_CR27","doi-asserted-by":"publisher","first-page":"e1070","DOI":"10.1212\/NXI.0000000000001070","volume":"8","author":"C Zhang","year":"2021","unstructured":"Zhang C, Zhang TX, Liu Y et al (2021) B-cell compartmental features and molecular basis for therapy in autoimmune disease. Neurol Neuroimmunol Neuroinflamm 8(6):e1070. https:\/\/doi.org\/10.1212\/NXI.0000000000001070","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"11","key":"13118_CR28","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1002\/art.38798","volume":"66","author":"JD Jones","year":"2014","unstructured":"Jones JD, Hamilton BJ, Skopelja S et al (2014) Induction of interleukin-6 production by rituximab in human B cells. Arthritis Rheumatol 66(11):2938\u20132946. https:\/\/doi.org\/10.1002\/art.38798","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"13118_CR29","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.jocn.2010.12.011","volume":"18","author":"I Nakashima","year":"2011","unstructured":"Nakashima I, Takahashi T, Cree BA et al (2011) Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica in association with elevated serum BAFF levels. J Clin Neurosci 18(7):997\u2013998. https:\/\/doi.org\/10.1016\/j.jocn.2010.12.011","journal-title":"J Clin Neurosci"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13118-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13118-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13118-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T13:25:13Z","timestamp":1749907513000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13118-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,18]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["13118"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13118-9","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,18]]},"assertion":[{"value":"27 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}],"article-number":"406"}}